Irini Flouri

ScholarGPS® ID: 43388745211996

Affiliation
University of Crete, Rethymnon, Greece
Affiliation History

Field
Medicine
Discipline
Rheumatology
Top Specialties
Arthritis | Rheumatoid Arthritis | Biological Agent
Metrics Summary
Publication Count
29
Predicted Citations
192
Predicted h-index
5
Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

  • Publications
  • Books
  • Patents
  • NIH/NSF
You must register and claim your profile to add or remove publications from it.
... publications
FILTER BY:
Year
Type
Specialty
Affiliations
Access
Co-Authors
Add
Delete
AB0894 TREAT-TO-TARGET STRATEGY IMPLEMENTATION IN SPONDYLOARTHRITIS PATIENTS WITH HIGH DISEASE ACTIVITY IN REAL-WORLD CLINICAL PRACTICE: A CROSS-SECTIONAL SINGLE-CENTER STUDY (conference)
Flouri, I. | Avgoustidis, N. | Repa, A. | Pateromichelaki, K. | Pitsigavdaki, S. | Marolachaki, E. | Emmanouilidou, E. | Dobysh, O. | Kalogiannaki, E. | Nikoloudaki, M. | ... | Sidiropoulos, P.
EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria (2024)
10.1136/annrheumdis-2024-eular.5260
Cite | Source
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progre (journal article)
Pitsigavdaki, Sofia | Nikoloudaki, Myrto | Garantziotis, Panagiotis | Silvagni, Ettore | Repa, Argyro | Marangoni, Antonio | Flouri, Irini | Avgoustidis, Nestor | Parperis, Konstantinos | Fanouriakis, Antonis | ... | Bertsias, George
Annals of the Rheumatic Diseases, volume 83, issue 4, pages 464-474 (2024).
10.1136/ard-2023-224919
Cited by (2) | Cite | Source
P70 Exposure to DORIS ≥50% of time and to LLDAS ≥60% of observation time exhibit the best combination of feasibility and protection against adverse outcomes in moderate-to-severe SLE (conference)
Pitsigavdaki, Sofia | Nikoloudaki, Myrto | Garantziotis, Panagiotis | Silvagni, Ettore | Repa, Argyro | Marangoni, Antonio | Flouri, Irini | Avgoustidis, Nestor | Parperis, Konstantinos | Govoni, Marcello | ... | Bertsias, George
14th European Lupus Meeting, Bruges, Belgium, March 19–22, 2024 (2024)
10.1136/lupus-2024-el.124
Cite | Source
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis (journal article)
Bertsias, Antonios | Flouri, Irini D | Repa, Argyro | Avgoustidis, Nestor | Kalogiannaki, Eleni | Pitsigavdaki, Sofia | Bertsias, George | Sidiropoulos, Prodromos
RMD Open, volume 10, issue 1, pages e003808- (2024).
10.1136/rmdopen-2023-003808
Cited by (1) | Cite | Source
Comorbidities Burden and Implementation of the Treat–to–Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides (journal article)
Flouri, Irini D. | Repa, Argyro | Avgoustidis, Nestor | Pitsigavdaki, Sofia | Pateromichelaki, Katerina | Marolachaki, Eleni | Terizaki, Maria | Nikoloudaki, Myrto | Eskitzis, Anastasios | Kalogiannaki, Eleni
Mediterranean Journal of Rheumatology, volume 34, issue 4, pages 581- (2023).
10.31138/mjr.310723.cba
Cite | Source
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients (journal article)
Goutakoli, Panagiota | Papadaki, Garyfalia | Repa, Argyro | Avgoustidis, Nestor | Kalogiannaki, Eleni | Flouri, Irini | Bertsias, Antonios | Zoidakis, Jerome | Samiotaki, Martina | Bertsias, George | ... | Sidiropoulos, Prodromos
Cells, volume 12, issue 24, pages 2808- (2023).
10.3390/cells12242808
Cited by (1) | Cite | Source
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study (journal article)
Flouri, Irini | Goutakoli, Panagiota | Repa, Argyro | Bertsias, Antonios | Avgoustidis, Nestor | Eskitzis, Anastasios | Pitsigavdaki, Sofia | Kalogiannaki, Eleni | Terizaki, Maria | Bertsias, George | Sidiropoulos, Prodromos
Rheumatology International, volume 44, issue 2, pages 249-261 (2023).
10.1007/s00296-023-05455-7
Cite | Source
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study (journal article)
Nikoloudaki, Myrto | Nikolopoulos, Dionysis | Koutsoviti, Sofia | Flouri, Irini | Kapsala, Noemin | Repa, Argyro | Katsimbri, Pelagia | Theotikos, Evangelos | Pitsigavdaki, Sofia | Pateromichelaki, Katerina | ... | Bertsias, George
Frontiers in Immunology, volume 13 (2023).
10.3389/fimmu.2022.1074044
Cited by (7) | Cite | Source
Cost of Illness, Quality of Life, and Work Productivity in Axial Spondyloarthritis Patients Receiving Biological Treatments in Greece (journal article)
Kougkas, Nikolaos | Mylonas, Charalambos | Avgoustidis, Nestor | Flouri, Irini | Sidiropoulos, Prodromos | Dimitroulas, Theodoros | Garyfallos, Alexandros
Mediterranean Journal of Rheumatology, volume 34, issue 1, pages 37- (2023).
10.31138/mjr.34.1.37
Cite | Source
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study (journal article)
Bertsias, Antonios | Avgoustidis, Nestor | Papalopoulos, Ioannis | Repa, Argyro | Kougkas, Nikolaos | Kalogiannaki, Eleni | Bertsias, Georgios | Flouri, Irini | Sidiropoulos, Prodromos
Arthritis Research & Therapy, volume 24, issue 1 (2022).
10.1186/s13075-022-02826-6
Cited by (4) | Cite | Source
Population Characteristics, Symptoms, and Risk Factors of Idiopathic Chilblains: A Systematic Review, Meta-Analysis, and Meta-Regression (journal article)
Kapnia, Areti K. | Ziaka, Styliani | Ioannou, Leonidas G. | Flouri, Irini | Dinas, Petros C. | Flouris, Andreas D.
Biology, volume 11, issue 11, pages 1651- (2022).
10.3390/biology11111651
Cite | Source
Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients (journal article)
Sénard, Thomas | Flouri, Irini | Vučković, Frano | Papadaki, Garyfalia | Goutakoli, Panagiota | Banos, Aggelos | Pučić-Baković, Maja | Pezer, Marija | Bertsias, George | Lauc, Gordan | Sidiropoulos, Prodromos
Arthritis Research & Therapy, volume 24, issue 1 (2022).
10.1186/s13075-022-02897-5
Cited by (5) | Cite | Source
AB0375 IN PATIENTS STARTING ETANERCEPT, MALE SEX, ABSENCE OF COMORBIDITIES AND NO csDMARDs CO-ADMINISTRATION ARE INDEPENDENT PREDICTORS OF LONG-TERM (MORE THAN 3 YEARS) PERSISTENCE TO THERAPY, IRRESPECTIVELY OF THE CLINICAL DIAGNOSIS. (journal article)
Flouri, I. | Repa, A. | Avgustidis, N. | Eskitzis, A. | Molla Ismail Sali, A. | Pitsigavdaki, S. | Pateromichelaki, K. | Bertsias, A. | Kalogiannaki, E. | Terizaki, M. | ... | Sidiropoulos, P.
Annals of the Rheumatic Diseases, volume 81, issue Suppl 1, pages 1314.2-1315 (2022).
10.1136/annrheumdis-2022-eular.4826
Cite | Source
AB0265 RHEUMATOID ARTHRITIS PATIENTS HOSPITALIZED FOR A SERIOUS INFECTION HAVE HIGH INCIDENCE OF SEPSIS WHILE THOSE ON bDMARDs HAVE LOWER MORTALITY COMPARED TO THOSE ON csDMARDs (journal article)
Tzagkarakis, E. | Flouri, I. | Facondi, I. | Kalogiannaki, E. | Ilia, S. | Briassoulis, G. | Sidiropoulos, P.
Annals of the Rheumatic Diseases, volume 81, issue Suppl 1, pages 1259-1259 (2022).
10.1136/annrheumdis-2022-eular.2064
Cited by (1) | Cite | Source
AB0090 BASELINE IgG-Fc N-GLYCOSYLATION PROFILE IS ASSOCIATED WITH LONG-TERM OUTCOME IN A COHORT OF EARLY INFLAMMATORY ARTHRITIS PATIENTS (journal article)
Sénard, T. | Flouri, I. | Vučković, F. | Papadaki, G. | Goutakoli, P. | Banos, A. | Pučić-Baković, M. | Pezer, M. | Bertsias, G. | Lauc, G. | Sidiropoulos, P.
Annals of the Rheumatic Diseases, volume 81, issue Suppl 1, pages 1176.2-1177 (2022).
10.1136/annrheumdis-2022-eular.4480
Cite | Source
POS0368 EARLY (3 MONTHS) IMPROVEMENT IN PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY PREDICTS LONG-TERM RETENTION OF BELIMUMAB TREATMENT IN SLE: A MULTICENTRE OBSERVATIONAL STUDY OF 184 PATIENTS (journal article)
Nikoloudaki, M. | Nikolopoulos, D. | Koutsoviti, S. | Flouri, I. | Kapsala, N. | Repa, A. | Katsimpri, P. | Theotikos, E. | Pitsigavdaki, S. | Pateromichelaki, K. | ... | Bertsias, G.
Annals of the Rheumatic Diseases, volume 81, issue Suppl 1, pages 437-438 (2022).
10.1136/annrheumdis-2022-eular.4735
Cite | Source
Distinct Long-Term Disease Activity Trajectories Differentiate Early on Treatment with Etanercept in Both Rheumatoid Arthritis and Spondylarthritis Patients (journal article)
Flouri, Irini D. | Repa, Argyro | Bertsias, Antonios | Avgoustidis, Nestor | Eskitzis, Anastasios | Pitsigavdaki, Sofia | Kalogiannaki, Eleni | Terizaki, Maria | Bertsias, George | Sidiropoulos, Prodromos
SSRN Electronic Journal (2022).
10.2139/ssrn.4232783
Cite | Source
OP0299 IN RHEUMATOID ARTHRITIS PATIENTS HIGHER NUMBER OF COMORBIDITIES PREDICTS 6-MONTH INSUFFICIENT RESPONSE TO FIRST BIOLOGIC THERAPY AND EVENTUAL CATEGORIZATION OF THE DISEASE AS DIFFICULT-TO-TREAT (journal article)
Flouri, I. | Repa, A. | Avgustidis, N. | Kougkas, N. | Eskitzis, A. | Molla Ismail Sali, A. | Pitsigavdaki, S. | Pateromichelaki, K. | Kalogiannaki, E. | Terizaki, M. | ... | Sidiropoulos, P.
Annals of the Rheumatic Diseases, volume 80, issue Suppl 1, pages 184.2-184 (2021).
10.1136/annrheumdis-2021-eular.4110
Cite | Source
POS0941 IN SPONDYLOARTHRITIS PATIENTS THE PRESENCE OF COMORBIDITIES IS AN INDEPENDENT PREDICTOR OF INSUFFICIENT RESPONSE TO THERAPY WITH BIOLOGIC AGENTS AND TREATMENT DISCONTINUATION (journal article)
Flouri, I. | Kougkas, N. | Avgustidis, N. | Repa, A. | Eskitzis, A. | Molla Ismail Sali, A. | Pitsigavdaki, S. | Pateromichelaki, K. | Kalogiannaki, E. | Bertsias, G. | Sidiropoulos, P.
Annals of the Rheumatic Diseases, volume 80, issue Suppl 1, pages 733.2-734 (2021).
10.1136/annrheumdis-2021-eular.4222
Cite | Source
POS0580 COMORBIDITY BURDEN IS HIGH IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS STARTING BIOLOGICS AND PREDICTS THE INCIDENCE OF SERIOUS ADVERSE EVENTS DURING THERAPY (journal article)
Flouri, I. | Repa, A. | Avgustidis, N. | Kougkas, N. | Eskitzis, A. | Molla Ismail Sali, A. | Pitsigavdaki, S. | Pateromichelaki, K. | Kalogiannaki, E. | Terizaki, M. | ... | Sidiropoulos, P.
Annals of the Rheumatic Diseases, volume 80, issue Suppl 1, pages 523.2-523 (2021).
10.1136/annrheumdis-2021-eular.3956
Cite | Source